Abstract
Epigenetic modification has recently been recognized as an important factor in the development of therapy resistance in cancer. Hence, histone deacetylase inhibitors as potential epigenetic modifiers are an emerging class of novel cancer therapeutics and have been extensively studied. Here, we review the role of histone deacetylase inhibitors in the treatment of breast cancer as single agents as well as in combination with chemotherapeutic, hormonal, and targeted agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
